CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
about
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemiaReplication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.VEGF/VEGFR signalling as a target for inhibiting angiogenesis.A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.Modulation of DNA methylation by a sesquiterpene lactone parthenolide.AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Investigational drugs targeting FLT3 for leukemia.Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.Bench to bedside targeting of FLT3 in acute leukemia.FMS-like tyrosine kinase 3 inhibitors: a patent review.Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy.New targeted therapies for renal cell carcinoma.Blastic leukaemias (AML): a biologist's view.Novel tyrosine kinase inhibitors for renal cell carcinoma.Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint.CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations.Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine
P2860
Q27851612-2B643255-0BB5-4E1E-A45F-463AA5896372Q28608331-F1856D78-F446-4BCA-B54C-442604331D1FQ33842529-11664B6B-9C10-46B8-A7B8-DFC833FC854CQ34120364-18C97B86-5C93-4B85-B7F4-361E04D78D9BQ34591403-4F6CB4F2-5C8D-4239-83E2-B058859A60ABQ35018563-A9A20878-7435-4C91-8C09-3EF18471AD02Q35083267-F7048176-A364-480C-AEBF-C4326330E3E8Q35742395-2AC05D21-8C25-40A9-88FF-07A9D41458CDQ36186386-1DBEAD6C-6E8F-4714-AB61-B6D6755B2AAAQ36555872-2BF1AFDC-BA56-487C-95FC-28F856B9D81EQ36677407-114AC69D-6667-4F71-B257-1FB6D280D5A1Q36909540-C8CE4BB1-23FE-4D83-8DE1-A47C586355A5Q37061044-6FBB6CCF-9BE3-40A4-BC1A-70361BB72190Q37113677-CDD22240-FDA3-4B50-A735-7A594DEABF7FQ37168514-D0FE7E41-19A8-42E9-9291-1C47A07D8184Q37373040-6F460FC0-7FF2-4E88-A26B-C6864FE2E76EQ37495206-47493544-1B66-4BE5-BE76-5DE670758101Q37577934-F19F0F5C-CBE3-4632-9A94-000F53BD601EQ37624735-C9C02908-C6CA-4DBE-84DF-5B1E18034F60Q37635256-97F54F4A-EE34-4A73-839D-A51799DAF492Q37717519-A63B0D5D-71C6-4851-BD66-247307EEF496Q37724957-66C0E66D-A5AD-4531-8147-B3BE835D110BQ37842585-6368FF9C-7A2D-4C29-BC7B-13323884AF22Q37849781-2F7A06E9-D084-4339-8967-1E2B4B6C33A5Q37867122-175B96B9-2468-4F8A-B28C-917EA6A1C44BQ38026774-407C3DF5-5BA0-4EAB-8AF8-6A3565D02893Q38168944-BD8B3226-AC00-4213-BE9C-E2B5EB89EDB1Q38289046-35E65913-56A1-44C0-B722-F68C17C859A4Q39172796-C099025A-F621-40B0-9264-61179880E5FAQ40214485-9706643C-50F2-464D-BA84-B20FBBADBFC9Q41092608-0F59C24E-101E-4EEE-81E1-942A5B059820Q41923223-48932094-9CA2-4218-BF2B-17AAB0169773Q53075287-C193D6CA-DC14-434C-990A-2DD9FE5147CFQ53142724-0013D1E0-3CBD-417B-8B15-8FC3718850B7Q53239474-1686050E-AD55-447E-AEAB-45CE910A67E0Q53533566-2014AC58-2CAC-4061-8E98-37398056F83FQ57022275-E7F6EE96-3958-406C-A89E-56DB9A2EF35D
P2860
CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@en
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@nl
type
label
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@en
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@nl
prefLabel
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@en
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@nl
P2093
P1476
CHIR-258: a potent inhibitor o ...... an acute myelogenous leukemia.
@en
P2093
Carla Heise
Cheryl Goldbeck
Daniel E Lopes de Menezes
Evelyn N Garrett
Lee Shephard
Marion Wiesmann
Sang H Lee
Sharianne G Louie
P304
P356
10.1158/1078-0432.CCR-05-0358
P407
P577
2005-07-01T00:00:00Z